AD ADTX Aditxt, Inc. Loading... : Investor Sentiment and Bull/Bear Views

The author owns ADTX and argues the definitive business combination valuing Ignite Proteomics at about $150 million, with Ignite expected to become a separate publicly traded company while ADTX remains public, makes the story more interesting than most realize. He notes a simple math exercise using approximately 997.9 million shares outstanding implies about $0.15 per share of Ignite value, though he explicitly says this is not a prediction or price target. The catalyst is successful closing of the deal and management execution; stated risks include unmet closing conditions, financing/regulatory approvals, dilution from convertible notes, and micro-cap biotech volatility.

Goldman Sachs reports that the top five most active retail names account for nearly 34% of total shares traded today, indicating strong retail footprint despite the memory rout.

The author calculates that ADTX's 3,250.50% annual borrow rate equals roughly 8.91% daily cost to short sellers, meaning a month-long short could pay more than 2.5x the position's value in fees. He cites short interest around 11.44% of float per MarketBeat and argues this pressure on shorts explains why the stock stays green despite heavy shorting. He frames the borrow rate as the catalyst for continued upward movement, noting 'another leg up.'

The author argues ADTX's borrow rate of 2,875% (later 3,250.50%) means short sellers pay roughly 8.15% of position value daily, forcing margin calls and liquidations. He contends this short squeeze dynamic will drive the stock higher, stating 'next leg up coming' and that the stock 'can't go red if it wanted to.' The stated risk is implicit in the extreme borrow dynamics, which he frames as hurting shorts rather than longs.

The author argues ADTX is a toxic death spiral because the company relies on toxic at-the-market convertible notes, creditors convert and dump shares into the market, and the true outstanding share count has likely exploded to over 30 million after a 1-for-27 reverse split (following a 1-for-8 split in March). They conclude that buying the stock only provides exit liquidity to creditors and Wall Street funds, and urge investors to stay away. The main stated risk is that buyers will continue to fund creditor exits as dilution proceeds daily.

The author argues Aditxt's publicly reported share count of 815,921 is unusable: a 13D filer reporting 3,420,439 shares would equal 419% of the company and attached a footnote calling the count stale, while two other same-day filers quoted that exact number as ~10% of the company. The mechanism is that filings, market cap and float data on this listed security are self-contradictory, so it cannot be valued on reported figures. The stated catalyst/evidence is the same-day SEC docket showing one filer flagging the count as fiction while others cite it as scripture, plus over three billion shares trading in a company screens say has 815,921 shares. The implied risk is that any position is taken against data that no one, including a 10% holder, can confirm.

The author argues ADTX should not delist because it just acquired a subsidiary company for $150 million, which they view as a growth move. The implied mechanism is that the acquisition adds value relative to the current market cap, making the company look undervalued. The author acknowledges awareness of weak revenue and market cap but still frames the deal as bullish. No explicit time horizon or risk beyond the acknowledged weak fundamentals is given.

Author argues ADTX is a damaged holding company whose market price discounts its assets, especially Ignite Proteomics, which was recently acquired and tied to a planned public listing valuing it around $150M. He sees the catalyst as Ignite being separated, listed, financed, or beginning to show testing revenue from its 10,000-patient oncology registry, which could generate about $13M and outcomes data. Main stated risks are tiny revenue, low cash, large losses, brutal dilution, reverse splits, Nasdaq delisting risk, and possible zero.

Author is bullish on ADTX, claiming Reddit retail may own 70–80% of open-market shares and that thin available supply could lead to price discovery. The stated catalyst is new interim CEO Jeffrey M. Busch, appointed to drive commercialization, with the author sensing a restructuring; the main stated risk is delisting and losing the entire investment.

The author argues that ADTX's share count is far larger than the ~800k float bulls believe, because the company has continually diluted and reverse split since listing. A filing more than a week ago showed a single entity holding over 2 million shares, undermining the low-float squeeze thesis. The implied risk is that anyone buying on a low-float narrative is misjudging the actual supply of shares.

The author argues Aditxt’s new interim CEO Jeffrey Busch is pivoting from portfolio acquisitions to operational execution, focusing on commercializing Ignite Proteomics’ precision oncology diagnostics. The mechanism is converting Medicare reimbursement and Dana-Farber collaborations into recurring revenue to restore Nasdaq compliance. Catalyst/timeframe: the September 30, 2026 transaction deadline; main stated risk is failure to lift equity above Nasdaq limits, leading to an OTC pivot.

The author argues ADTX is undervalued at pennies relative to its true value because new interim CEO Jeffrey M. Busch has a strong track record running a billion-dollar market cap healthcare real estate company (GMRE/XRN) and holds presidential appointments. The pending merger with Ignite Proteomics Holdings (pubco) will create an entity holding $150 million worth of shares, which the author believes supports a valuation of at least $0.25-$0.50 per share despite 185 million shares outstanding. Busch has only been CEO for less than a month and is executing a restructuring. The main risk is the large share count and the speculative nature of the merger.

The author is long ADXT with 60,000 shares, arguing the SPAC merger that pays ADXT $150 million in shares for Ignite Proteomics going independent would be very bullish at the current ~$13k market cap. A more conservative $30 million valuation could pay off debt and cover $11 million in liabilities, leaving the rest as assets, and Ignite's innovative protein-pathway tumor detection technology targets a proteomics market the author cites as over $39 billion. The main stated risk is that if the stock does not get above $0.10, a delisting notice will be sent.

Author argues ADTX is an asymmetric deep-value microcap: its wholly owned subsidiary Ignite Proteomics was assigned an implied valuation of roughly $150 million in a definitive agreement to make it an independent public company, so the market may be pricing the remaining assets (Pearsanta diagnostics, immune modulation programs, Evofem-related assets) at almost nothing. The stated catalysts are closing the Ignite transaction, additional partnerships, asset monetization, improved financing terms, Nasdaq compliance progress and commercial revenue growth, supported by newly appointed interim CEO Jeffrey Busch's commercialization focus. The main stated risk is that the bull case requires reducing dilution pressure, generating commercial revenue, maintaining access to capital and avoiding further setbacks — if management fails, the stock could continue to struggle.

The author lists Aditxt among companies that filed reverse-split paperwork across 7 separate quarters in two years, framing them as dying stocks that keep resetting the delisting countdown. He argues the reverse split fixes nothing about the business and that these firms sell new stock at the same time, so the share count balloons right after being crushed down. The takeaway is to avoid such names.